ARTICLE | Clinical News
Odonate starts Phase III trial of tesetaxel to treat breast cancer
January 5, 2018 10:52 PM UTC
Odonate Therapeutics Inc. (NASDAQ:ODT) began the Phase III CONTESSA trial of tesetaxel (DJ-927) to treat locally advanced or metastatic breast cancer. The open-label, international trial will compare 27 mg/m2 oral tesetaxel once every 21 days plus capecitabine vs. capecitabine alone.
The trial will enroll about 600 patients with hormone receptor-positive, HER2-negative breast cancer. CONTESSA’s primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR) and disease control rate (DCR). ...
BCIQ Target Profiles